These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 29138342)

  • 1. Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes.
    Iñarrairaegui M; Melero I; Sangro B
    Clin Cancer Res; 2018 Apr; 24(7):1518-1524. PubMed ID: 29138342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
    Roth GS; Decaens T
    Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies.
    Zarlashat Y; Mushtaq H; Pham L; Abbas W; Sato K
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
    Harding JJ
    Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status and future of targeted-immune combination for hepatocellular carcinoma.
    Hao L; Li S; Ye F; Wang H; Zhong Y; Zhang X; Hu X; Huang X
    Front Immunol; 2024; 15():1418965. PubMed ID: 39161764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Kudo M
    Oncology; 2017; 92 Suppl 1():50-62. PubMed ID: 28147363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects.
    Roudi R; D'Angelo A; Sirico M; Sobhani N
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108322. PubMed ID: 34735916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
    Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
    Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC].
    Xiao ZL; Wang P; Lei LP; Zhou HB; Hu HP
    Zhonghua Gan Zang Bing Za Zhi; 2019 Sep; 27(9):732-736. PubMed ID: 31594104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
    Duffy AG; Ulahannan SV; Makorova-Rusher O; Rahma O; Wedemeyer H; Pratt D; Davis JL; Hughes MS; Heller T; ElGindi M; Uppala A; Korangy F; Kleiner DE; Figg WD; Venzon D; Steinberg SM; Venkatesan AM; Krishnasamy V; Abi-Jaoudeh N; Levy E; Wood BJ; Greten TF
    J Hepatol; 2017 Mar; 66(3):545-551. PubMed ID: 27816492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding JJ; El Dika I; Abou-Alfa GK
    Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma.
    Hou K; Xu X; Ge X; Jiang J; Ouyang F
    Biofactors; 2024; 50(2):250-265. PubMed ID: 37921427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
    Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.
    Sové RJ; Verma BK; Wang H; Ho WJ; Yarchoan M; Popel AS
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological landscape and immunotherapy of hepatocellular carcinoma.
    Prieto J; Melero I; Sangro B
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.